More Than Face Value: India’s Sun Pharma Buys Dusa To Build Specialty Dermatology Business
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma is attempting to build a specialty dermatology business in the U.S., one that has limited competition and a longer term revenue visibility, but some Dusa shareholders aren’t happy.